Arcus Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Number of shares of common stock · Common stock and additional paid-in capital · Accumulated deficit · Accumulatedothercomprehensive loss · Totalstockholders’ equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at December 31, 2024 | 92.2 | $1,617 | $(1,132) | $— | $485 | ||||||
| Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity) | 13.6 | 142 | — | — | 142 | ||||||
| Issuance of common stock in connection with our equity award programs | 0.1 | — | — | — | — | ||||||
| Stock-based compensation | — | 16 | — | — | 16 | ||||||
| Net loss | — | — | (112) | — | (112) | ||||||
| Balance at March 31, 2025 | 105.9 | 1,775 | (1,244) | — | 531 | ||||||
| Issuance of common stock in connection with our equity award programs | 0.5 | 3 | — | — | 3 | ||||||
| Stock-based compensation | — | 15 | — | — | 15 | ||||||
| Net income | — | — | — | — | — | ||||||
| Balance at June 30, 2025 | 106.4 | 1,793 | (1,244) | — | 549 | ||||||
| Issuance of common stock (see Note 13, Stockholders' equity) | 0.7 | 8 | — | — | 8 | ||||||
| Stock-based compensation | — | 14 | — | — | 14 | ||||||
| Net loss | — | — | (135) | — | (135) | ||||||
| Balance at September 30, 2025 | 107.1 | $1,815 | $(1,379) | $— | $436 | ||||||
| Balance at December 31, 2025 | 125.3 | $2,116 | $(1,485) | $— | $631 | ||||||
| Issuance of common stock in connection with our equity award programs | 0.2 | 3 | — | — | 3 | ||||||
| Stock-based compensation | — | 19 | — | — | 19 | ||||||
| Other comprehensive loss | — | — | — | (1) | (1) | ||||||
| Net loss | — | — | (128) | — | (128) | ||||||
| Balance at March 31, 2026 | 125.5 | 2,138 | (1,613) | (1) | 524 | ||||||
| Issuance of common stock in connection with our equity award programs | 1.5 | 16 | — | — | 16 | ||||||
| Stock-based compensation | — | 15 | — | — | 15 | ||||||
| Net loss | — | — | (91) | — | (91) | ||||||
| Balance at June 30, 2026 | 127.0 | 2,169 | (1,704) | (1) | 464 | ||||||
| Issuance of common stock in connection with our equity award programs | 0.6 | 7 | — | — | 7 | ||||||
| Stock-based compensation | — | 16 | — | — | 16 | ||||||
| Other comprehensive loss | — | — | — | (1) | (1) | ||||||
| Net loss | — | — | (128) | — | (128) | ||||||
| Balance at September 30, 2026 | 127.6 | $2,192 | $(1,832) | $(2) | $358 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.